{"id":"NCT02013609","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment","officialTitle":"Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11","primaryCompletion":"2014-09","completion":"2014-10","firstPosted":"2013-12-17","resultsPosted":"2016-03-29","lastUpdate":"2016-03-29"},"enrollment":48,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["MDD"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":[]}],"arms":[{"label":"Brexpiprazole","type":"EXPERIMENTAL"}],"summary":"To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response in a school or work environment.","primaryOutcome":{"measure":"Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Brexpiprazole","deltaMin":-18.1,"sd":1.4}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":24,"countries":["United States"]},"refs":{"pmids":["34894307"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":["Headache","Weight increased","Somnolence","Anxiety","Nausea"]}}